The FDA has granted breakthrough therapy designation for Johnson & Johnson’s Zejula in metastatic prostate cancer patients with certain gene mutations. But J&J is still facing a tough rival in Lynparza from AstraZeneca and Merck, especially in light of new data presented earlier this week at a closely watched oncology conference.
